Iptacopan improves hemoglobin to near-normal levels in PNH patients
Research molecule of Novartis, Iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naive paroxysmal nocturnal hemoglobinuria patients, as per recent trials.
The trial met its primary endpoint and demonstrated clinically meaningful benefits across secondary endpoints. These data were presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).